Clinical trial data key to personalization of treatment decisions
By
MIT study explores the key factors behind patient outcomes in clinical trials evaluating new treatments for non-small-cell lung cancer.
By
MIT study explores the key factors behind patient outcomes in clinical trials evaluating new treatments for non-small-cell lung cancer.
By
MIT Sloan and CSAIL researchers apply artificial intelligence techniques to one of the largest datasets of clinical trial outcomes to handicap the drug and device approval process
We push the boundaries of finance to solve complex problems and fuel progress in the world through the MIT finance ecosystem – a unique global network of people, programs, research, and partnerships.
By
The MIT Laboratory for Financial Engineering (LFE) and Informa Pharma Intelligence announced a new initiative, Project ALPHA (Analytics for Life-sciences Professionals and Healthcare Advocates).
By
In a new book, MIT roboticist Daniela Rus looks at the powers and limitations of robots and how humans can work with them to unlock new capabilities.
By
Machine learning is a powerful form of artificial intelligence that is affecting every industry. Here’s what you need to know about its potential and limitations and how it’s being used.
By
AI is a tool to get things done. To use it properly and generate value, organizations need the right capabilities — including a good understanding of data.
Ahead of the presidential inauguration, MIT Sloan's Professor Andrew Lo and other panelists described advances in their research and how these discoveries are being deployed to benefit the public.
By
Professors Retsef Levi and Karen Zheng discussed their work in addressing food and agriculture issues across the globe at MIT Sloan Reunion 2023.